Atria Investments Inc Has $4.53 Million Holdings in IQVIA Holdings Inc. $IQV

Atria Investments Inc boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 47.9% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 28,748 shares of the medical research company’s stock after buying an additional 9,312 shares during the period. Atria Investments Inc’s holdings in IQVIA were worth $4,530,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of IQV. Pacer Advisors Inc. increased its position in IQVIA by 5,036.1% during the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock worth $153,681,000 after buying an additional 854,732 shares during the last quarter. JPMorgan Chase & Co. increased its position in IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after buying an additional 798,534 shares during the last quarter. Nordea Investment Management AB increased its position in IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after buying an additional 606,391 shares during the last quarter. Hawk Ridge Capital Management LP acquired a new position in IQVIA during the first quarter worth $77,096,000. Finally, Nuveen LLC acquired a new position in IQVIA during the first quarter worth $76,328,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Down 0.0%

NYSE IQV opened at $216.43 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.84 and a current ratio of 0.70. The firm has a 50-day simple moving average of $197.12 and a 200 day simple moving average of $173.95. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $225.91. The stock has a market cap of $36.86 billion, a PE ratio of 29.69, a PEG ratio of 2.43 and a beta of 1.32.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter last year, the company earned $2.84 earnings per share. The firm’s revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares in the company, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the topic of several analyst reports. JPMorgan Chase & Co. increased their target price on shares of IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday. Redburn Partners set a $214.00 target price on shares of IQVIA in a research report on Wednesday, September 3rd. Stifel Nicolaus upped their price target on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a report on Wednesday. Robert W. Baird set a $258.00 price target on shares of IQVIA and gave the company an “outperform” rating in a report on Wednesday. Finally, Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $241.41.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.